Beryl Drugs Balance Sheet Health
Financial Health criteria checks 2/6
Beryl Drugs has a total shareholder equity of ₹89.2M and total debt of ₹50.9M, which brings its debt-to-equity ratio to 57.1%. Its total assets and total liabilities are ₹174.9M and ₹85.6M respectively. Beryl Drugs's EBIT is ₹13.3M making its interest coverage ratio 2.4. It has cash and short-term investments of ₹2.2M.
Key information
57.1%
Debt to equity ratio
₹50.94m
Debt
| Interest coverage ratio | 2.4x |
| Cash | ₹2.23m |
| Equity | ₹89.23m |
| Total liabilities | ₹85.64m |
| Total assets | ₹174.87m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 524606's short term assets (₹102.2M) exceed its short term liabilities (₹57.6M).
Long Term Liabilities: 524606's short term assets (₹102.2M) exceed its long term liabilities (₹28.1M).
Debt to Equity History and Analysis
Debt Level: 524606's net debt to equity ratio (54.6%) is considered high.
Reducing Debt: 524606's debt to equity ratio has increased from 43.1% to 57.1% over the past 5 years.
Debt Coverage: 524606's debt is not well covered by operating cash flow (16.1%).
Interest Coverage: 524606's interest payments on its debt are not well covered by EBIT (2.4x coverage).